| Identification | Back Directory | [Name]
Encainide | [CAS]
37612-13-8 | [Synonyms]
Encainide
Unii-sy3J0147nb
Encainide [inn:ban]
Encainide USP/EP/BP
4-Methoxy-N-(2-(2-(1-Methylpiperidin-2-yl)ethyl)phenyl)benzaMide | [Molecular Formula]
C22H28N2O2 | [MOL File]
37612-13-8.mol | [Molecular Weight]
352.475 |
| Hazard Information | Back Directory | [Description]
Encainide is a membrane-active class I c
agent with complex metabolism and clinical
pharmacology , . To date, its effectiveness
has been proved against ventricular arrhythmias. | [Uses]
Cardiac depressant (anti-arrhythmic. | [Definition]
ChEBI: Encainide is 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market. It has a role as an anti-arrhythmia drug and a sodium channel blocker. It is a member of piperidines and a member of benzamides. | [Brand name]
Enkaid
(Bristol Labs). | [World Health Organization (WHO)]
The membrane-stabilizing antiarrhythmic agent encainide was
introduced into medicine in the mid-1980's. The decision to delete the indications
for patients with asymptomatic and less severe symptomatic ventricular
arrhythmias was taken on the basis of the results of a trial (CAST study) that
showed a two-fold increase in deaths in post-myocardiac patients taking encainide
compared with the placebo group. (See also WHO comment for flecainide). | [Side effects]
Side effects include central nervous system
activity. | [Synthesis]
Encainide, 4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]-benzamide
(18.1.15), is synthesized by acylating 2-(1-methyl-2-piperidylethyl)aniline with 4-
methoxybenzoic acid chloride. The chemical structure of encainide is substantially
different than other local anesthetics and antiarrhythmics.
|
|
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|